Entacapone


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Adjunct to levodopa treatment in Parkinson's disease
Adult: 200 mg w/ each levodopa/dopa decarboxylase inhibitor dose. Max: 200 mg 10 times daily (2,000 mg daily). Gradually reduce levodopa dose by approx 10-30% or increase dosing interval w/in the 1st few wk of starting treatment.
Hepatic Impairment
Contraindicated.
Cách dùng
May be taken with or without food.
Chống chỉ định
Phaeochromocytoma, history of neuroleptic malignant syndrome and/or non-traumatic rhabdomyolysis. Hepatic impairment. Concomitant use w/ non-selective MAOIs.
Thận trọng
Patient w/ biliary obstruction, ischaemic heart disease. Avoid abrupt withdrawal. Pregnancy and lactation.
Phản ứng phụ
Abdominal pain, nausea, vomiting, diarrhoea, constipation, colitis, dry mouth, dyskinesia, dizziness, nightmares, insomnia, hallucinations, confusion, fatigue, increased sweating, behavioural disturbances; urine, skin, hair, beard and nail discolourations; cholestatic hepatitis, rhabdomyolysis. Rarely, agitation, urticaria, erythematous or maculopapular rash, anorexia, wt decrease, increased liver enzymes.
Potentially Fatal: Neuroleptic malignant syndrome (NMS)-like syndrome (w/ abrupt reduction or withdrawal).
Thông tin tư vấn bệnh nhân
This drug may cause reddish-brown discolouration of urine. When given w/ levodopa, may cause dizziness and symptomatic orthostatism, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor BP, hepatic function, mental status and impulse control disorders, daytime sleepiness, serum Fe, wt loss; signs/symptoms of Parkinson's disease, neuroleptic malignant syndrome (if abrupt withdrawal is required); regular dermatologic examination.
Quá liều
Symptoms: Decreased activity, confusion, somnolence, hypotonia, urticaria, skin discolouration. Management: Symptomatic treatment.
Tương tác
May interfere w/ metabolism of other drugs metabolised by COMT (e.g. rimiterole). May aggravate levodopa-induced orthostatic hypotension. Risk of dopaminergic effects w/ dopamine agonists (e.g. bromocriptine), selegiline, amantadine. May form chelates w/ Fe in the GI tract. Additive sedative effects w/ other CNS depressants.
Potentially Fatal: Concomitant use w/ non-selective MAOIs (e.g. phenelzine) may result in inhibition of principal pathways in the metabolism of catecholamines.
Food Interaction
May potentiate the sedative effect of alcohol.
Tác dụng
Description: Entacapone decreases the metabolic loss of levodopa to 3-O-methyldopa (3-OMD) through inhibition of COMT enzyme leading to an increased levodopa concentration, thus, extending the duration and effect in the brain.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Bioavailability: 29-46%. Time to peak plasma concentration: Approx 1 hr.
Distribution: Plasma protein binding: Approx 98% (primarily to albumin).
Metabolism: Undergoes extensive first-pass metabolism; isomerisation to the cis-isomer, followed by direct glucuronidation of the parent and cis-isomer.
Excretion: Mainly via faeces (10%); urine (approx 10-20%, as glucuronide conjugates). Elimination half-life: Approx 1.6-3.4 hr.
Đặc tính

Chemical Structure Image
Entacapone

Source: National Center for Biotechnology Information. PubChem Database. Entacapone, CID=5281081, https://pubchem.ncbi.nlm.nih.gov/compound/Entacapone (accessed on Jan. 21, 2020)

Bảo quản
Store at 25°C.
Phân loại MIMS
Phân loại ATC
N04BX02 - entacapone ; Belongs to the class of other dopaminergic agents used in the management of Parkinson's disease.
References
Anon. Entacapone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 27/11/2015.

Buckingham R (ed). Entacapone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 27/11/2015.

Comtan Tablet, Film Coated (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 27/11/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Entacapone. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 27/11/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Entacapone từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in